
ASX Announcement and Media Release

21 June, 2005

SciGen Limited

Insulin commercialization agreement for Bangladesh

The Directors of SciGen Limited (“SciGen” or the “Company”) are pleased to announce that the Company has executed a commercialization agreement with Rangs Pharmaceuticals Ltd (“Rangs Pharma”) for the commercialization of Insulin in Bangladesh. The execution of this agreement means that SciGen has insulin commercialization agreements in place for the major markets in the Indian Sub-Continent (India, Pakistan, Bangladesh and Sri Lanka).

Rangs Pharma is a member of the Rangs Group one of Bangladesh major corporations with ownership interests in eighteen companies. The Rangs Group is a conglomerate with business interests across a range of sectors including pharmaceuticals, deep sea fishing, real estate, petroleum, automobiles, electronics, banking, print media, broadcasting, insurance and IT.

Rangs Pharma’s pharmaceutical product portfolio includes antibiotics, cardiovascular, anti-inflammatory products and oral anti-diabetic. It is a fully integrated pharmaceutical company from research and development capability to manufacturing, distribution and sales & marketing.

Rang is contractually obligated to purchase an amount of finished product over the first five years of the agreement. The dollar value of the minimum purchases remains confidential.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton

Managing Director and CEO: Telephone: +61 2 9234 1700: Web: www.scigen.com.au